Nuvalent, Inc. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that Nuvalent, Inc. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($425.38M) | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | ($260.76M) | Feb 26, 2026 |
| FY2025 | Dec 31, 2023 | ($126.22M) | Feb 26, 2026 |
| FY2024 | Dec 31, 2022 | ($81.85M) | Feb 27, 2025 |
| FY2022 | Dec 31, 2021 | ($46.34M) | Mar 16, 2023 |
| FY2021 | Dec 31, 2020 | ($14.56M) | Mar 29, 2022 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($414.31M) | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | ($280.37M) | Feb 26, 2026 |
| FY2025 | Dec 31, 2023 | ($149.49M) | Feb 26, 2026 |
| FY2024 | Dec 31, 2022 | ($86.11M) | Feb 27, 2025 |
| FY2022 | Dec 31, 2021 | ($45.82M) | Mar 16, 2023 |
| FY2021 | Dec 31, 2020 | ($16.91M) | Mar 29, 2022 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $306.97M | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | $217.77M | Feb 26, 2026 |
| FY2025 | Dec 31, 2023 | $113.24M | Feb 26, 2026 |
| FY2024 | Dec 31, 2022 | $63.73M | Feb 27, 2025 |
| FY2022 | Dec 31, 2021 | $35.56M | Mar 16, 2023 |
| FY2021 | Dec 31, 2020 | $15.40M | Mar 29, 2022 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($275.21M) | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | ($185.06M) | Feb 26, 2026 |
| FY2025 | Dec 31, 2023 | ($99.74M) | Feb 26, 2026 |
| FY2024 | Dec 31, 2022 | ($64.97M) | Feb 27, 2025 |
| FY2022 | Dec 31, 2021 | ($40.00M) | Mar 16, 2023 |
| FY2021 | Dec 31, 2020 | ($14.95M) | Mar 29, 2022 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.41B | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | $1.14B | Feb 26, 2026 |
| FY2024 | Dec 31, 2023 | $732.38M | Feb 27, 2025 |
| FY2023 | Dec 31, 2022 | $482.46M | Feb 27, 2024 |
| FY2022 | Dec 31, 2021 | $293.82M | Mar 16, 2023 |
| FY2021 | Dec 31, 2020 | $10.65M | Mar 29, 2022 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $164.37M | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | $71.96M | Feb 26, 2026 |
| FY2024 | Dec 31, 2023 | $31.82M | Feb 27, 2025 |
| FY2023 | Dec 31, 2022 | $19.48M | Feb 27, 2024 |
| FY2022 | Dec 31, 2021 | $8.79M | Mar 16, 2023 |
| FY2021 | Dec 31, 2020 | $6.62M | Mar 29, 2022 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.25B | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | $1.07B | Feb 26, 2026 |
| FY2025 | Dec 31, 2023 | $700.56M | Feb 26, 2026 |
| FY2025 | Dec 31, 2022 | $462.98M | Feb 26, 2026 |
| FY2024 | Dec 31, 2021 | $285.04M | Feb 27, 2025 |
| FY2022 | Dec 31, 2020 | ($31.32M) | Mar 16, 2023 |
| FY2021 | Dec 31, 2019 | ($17.26M) | Mar 29, 2022 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($972.43M) | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | ($547.05M) | Feb 26, 2026 |
| FY2024 | Dec 31, 2023 | ($286.30M) | Feb 27, 2025 |
| FY2023 | Dec 31, 2022 | ($160.08M) | Feb 27, 2024 |
| FY2022 | Dec 31, 2021 | ($78.22M) | Mar 16, 2023 |
| FY2021 | Dec 31, 2020 | ($31.89M) | Mar 29, 2022 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $261.75M | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | $145.69M | Feb 26, 2026 |
| FY2024 | Dec 31, 2023 | $335.39M | Feb 27, 2025 |
| FY2023 | Dec 31, 2022 | $241.81M | Feb 27, 2024 |
| FY2022 | Dec 31, 2021 | $68.53M | Mar 16, 2023 |
| FY2021 | Dec 31, 2020 | $10.33M | Mar 29, 2022 |
| FY2021 | Dec 31, 2019 | $3.02M | Mar 29, 2022 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | (5) | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | (3) | Feb 26, 2026 |
| FY2025 | Dec 31, 2023 | (2) | Feb 26, 2026 |
| FY2024 | Dec 31, 2022 | (1) | Feb 27, 2025 |
| FY2022 | Dec 31, 2021 | (2) | Mar 16, 2023 |
| FY2021 | Dec 31, 2020 | (5) | Mar 29, 2022 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | (5) | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | (3) | Feb 26, 2026 |
| FY2025 | Dec 31, 2023 | (2) | Feb 26, 2026 |
| FY2024 | Dec 31, 2022 | (1) | Feb 27, 2025 |
| FY2022 | Dec 31, 2021 | (2) | Mar 16, 2023 |
| FY2021 | Dec 31, 2020 | (5) | Mar 29, 2022 |